Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Role of Private Label Agreements in Enhancing Access to Biosimilars
Panelists discuss how private label agreements facilitate biosimilar market entry by allowing manufacturers to collaborate on branding, distribution, and market access, ultimately expanding treatment options and potentially reducing health care costs.
EP: 1.Clinical Value of Biosimilars and the Role of Interchangeability
EP: 2.The Economic Impact of Biosimilars
EP: 3.Best Practices for Employers to Maximize Uptake of Biosimilars
Now Viewing
EP: 4.The Role of Private Label Agreements in Enhancing Access to Biosimilars
EP: 5.Key Structural and Operational Considerations for Biosimilar Adoption
EP: 6.Positioning Biosimilars in Clinical Practice
EP: 7.Assessing Patient Confidence With Biosimilars
EP: 8.The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars
EP: 9.The Growing Market for Biosimilars
EP: 10.Biosimilar Pricing Strategies: Understanding High-WAC and Low-WAC Models
EP: 11.The Biosimilar Shift: How PBMs Are Reshaping Formularies
EP: 12.The Road to Biosimilar Adoption: Navigating Interchangeability
EP: 13.How the IRA is Reshaping Biosimilar Adoption
EP: 14.Cost Savings Potential Associated With the Use of Biosimilars
EP: 15.Examining the Role of Interchangeability in Clinical Practice
EP: 16.Optimizing the Implementation of Biosimilars Into Formularies
EP: 17.Key Pearls for Collaborating With Manufacturers for Successful Uptake of Biosimilars
EP: 18.Working With Policy Makers to Effectively Implement Biosimilars
Video content above is prompted by the following:
- What is the role of private label agreements and how can they enhance access to biosimilars?
Related Videos
Related Content
In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel
June 24th 2025Article
In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.
Read More
